Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema

NCT02055911 ↗

Phase 4 Withdrawn Federal University of São Paulo Novartis · collab

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety of intravitreal ranibizumab repeated injections in patients with diabetic macular edema regarding maintenance of retinal ganglion cell function.

Timeline

Start: 2014-03
Primary completion: 2015-03
Completion: 2015-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ranibizumab	Monoclonal antibody	0.5 mg	Intravitreal

Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema

Summary

Timeline

Drugs

Indications